Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects With Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Apr 2010 Secondary endpoint 'Fasting glucose level' and "Postprandial glucose level' have been met in recipients of dutogliptin (400 mg/day) according to top-line results reported in a Phenomix Corporation media release.
21 Apr 2010 Top-line results have been reported in a Phenomix Corporation media release.
21 Apr 2010 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to top-line results reported in a Phenomix Corporation media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com